#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Nephroblastoma Pleural mesothelioma malignant Dent's disease Choroidal dystrophy Glomerulonephritis minimal lesion Central nervous system neoplasm Scleroderma associated digital ulcer Epilepsy Squamous cell carcinoma of the hypopharynx Castleman's disease Neuropathic arthropathy Vascular calcification Gastrooesophageal cancer Chronic graft versus host disease in skin Adult T-cell lymphoma/leukaemia refractory More trials…

    Learn about Rare Diseases

    Angiosarcoma metastatic – Life with Disease Lymphangiosarcoma – Life with Disease Langerhans’ cell histiocytosis – Basic Information Tuberous sclerosis complex – Diagnostics Breast angiosarcoma – Treatment Alveolar rhabdomyosarcoma – Life with Disease Congenital hypotransferrinaemia Hepatic angiosarcoma Acute respiratory distress syndrome – Treatment Usher’s syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    LUNSEKIMIG Calcium Polystyrene Sulfonate Fluconazole ABIRATERONE DECANOATE Streptococcus Pneumoniae Specific Nucleic Acid Sna-Xfsc Pf-06480605 Bezafibrate Panobinostat Tiemonium Methylsulphate Gabapentin Xenon (129Xe) Phleum Pratense Pollen Extract Nomegestrol Acetate HALOBETASOL PROPIONATE Bay 2927088 H2-Receptor Antagonists Vonafexor Regn5668 Bi-1910 More therapies…

    Learn about Your Condition

    Lung transplant Adrenogenital syndrome Caesarean section Alveolar bone defect Biliary adenoma Thyroid cancer Breast cancer metastatic Influenza Hyperphagia Coronary artery dissection Uterine leiomyoma Leiomyosarcoma metastatic Mantle cell lymphoma recurrent Tricuspid valve disease Dilated cardiomyopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Splenic marginal zone lymphoma

  • Epcoritamab for Adults with Relapsed or Refractory Marginal Zone Lymphoma: A Phase II Open‑Label Study

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Extranodal marginal zone B-cell lymphoma (MALT type)
    • Splenic marginal zone lymphoma
    • Nodal marginal zone B-cell lymphoma
    Investigated Drugs:
    • Epcoritamab
    Germany

  • Study of Obinutuzumab as First-Line Treatment for Adult Patients with Marginal Zone Lymphoma Who Are Not Eligible for Local Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Extranodal marginal zone B-cell lymphoma (MALT type)
    • Splenic marginal zone lymphoma
    • Nodal marginal zone B-cell lymphoma
    Investigated Drugs:
    • Obinutuzumab
    Germany

  • Study on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Extranodal marginal zone B-cell lymphoma (MALT type)
    • Splenic marginal zone lymphoma
    • Nodal marginal zone B-cell lymphoma
    Investigated Drugs:
    • Copanlisib Dihydrochloride
    • Rituximab
    Germany

  • Study Comparing Rituximab and Zanubrutinib with Rituximab Alone for Untreated Patients with Splenic Marginal Zone Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Rituximab
    • Zanubrutinib
    Austria Denmark France Italy Norway Spain +1

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!